The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006) · Nature Genetics · doi:10.1038/ng1861 · Cited by 1,193
HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574
HER-2 gene amplification can be acquired as breast cancer progresses
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Park, S. Y., Gönen, M., Kim, H. J., Michor, F., & Polyak, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40724 · Cited by 324
Self-citationComparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., & Larsimont, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf252 · Cited by 309
Tumor heterogeneity: biological implications and therapeutic consequences
Heppner, G. H., & Miller, B. E. (1983) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046903 · Cited by 307
Jackson, A. L., & Loeb, L. A. (1998) · Genetics · doi:10.1093/genetics/148.4.1483 · Cited by 253
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., Persons, D. L., Tubbs, R. R., & Hammond, M. E. H. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.611 · Cited by 239
Bartlett, J. M. S., Brookes, C. L., Robson, T., van de Velde, C. J. H., Billingham, L. J., Campbell, F. M., Grant, M., Hasenburg, A., Hille, E. T. M., Kay, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3677 · Cited by 193
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner, M., Järvinen, P., & Isola, J. J. (2001) · PubMed · Cited by 187
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7939 · Cited by 180
HER-2/neu expression in primary and metastatic breast cancer
Lower, E. E., Glass, E., Blau, R., & Harman, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9931-6 · Cited by 171
Gong, Y., Booser, D. J., & Sneige, N. (2005) · Cancer · doi:10.1002/cncr.20987 · Cited by 158
Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas
Regitnig, P., Schippinger, W., Lindbauer, M., Samonigg, H., & Lax, S. (2004) · The Journal of Pathology · doi:10.1002/path.1592 · Cited by 129
Szöllõsi, J., Balázs, M., Feuerstein, B. G., Benz, C. C., & Waldman, F. M. (1995) · PubMed · Cited by 121
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice
Ma, Y., Lespagnard, L., Durbecq, V., Paesmans, M., Desmedt, C., Gomez-Galdón, M., Veys, I., Cardoso, F., Sotiriou, C. P., Leo, A. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2256 · Cited by 108
Arnould, L., Arveux, P., Couturier, J., Gelly-Marty, M., Loustalot, C., Ettore, F., Sagan, C., Antoine, M., Penault-Llorca, F. M., Vasseur, B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3022 · Cited by 106
HeterogeneousHER2Gene Amplification
Bartlett, A. I., Starcyznski, J., Robson, T., MacLellan, A., Campbell, F., van de Velde, C. J. �., Hasenburg, A., Markopoulos, C. J., Seynaeve, C., Rea, D. W., et al. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp0en6aqmwetzz · Cited by 104
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
Brunelli, M., Manfrin, E., Martignoni, G., Miller, K., Remo, A., Reghellin, D., Bersani, S., Gobbo, S., Eccher, A., Chilosi, M., et al. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcp09vutzwzxbmj · Cited by 103
Allison, K. H., Dintzis, S. M., & Schmidt, R. A. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpxtzskbrip07w · Cited by 101
Fabi, A., Benedetto, A. D., Metro, G., Perracchio, L., Nisticò, C., Filippo, F. D., Ercolani, C., Ferretti, G., Melucci, E., Buglioni, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1920 · Cited by 97
Glöckner, S. C., Buurman, H., Kleeberger, W., Lehmann, U., & Kreipe, H. H. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000032371.16521.40 · Cited by 85
Cottu, P. H., Asselah, J., Lae, M. E., Pierga, J., Dieras, V. C., Mignot, L., Sigal‐Zafrani, B., & Vincent‐Salomon, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn021 · Cited by 82
Madarnas, Y., Trudeau, M., Franek, J. A., McCready, D. R., Pritchard, K. I., & Messersmith, H. J. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.013 · Cited by 77
Targeting chromosomal instability and tumour heterogeneity in HER2‐positive breast cancer
Burrell, R. A., Birkbak, N. J., Johnston, S. R. D., Reis-Filho, J. S., Szállási, Z., & Swanton, C. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22781 · Cited by 48
Shin, S. J., Hyjek, E. M., Early, E., & Knowles, D. M. (2006) · International Journal of Surgical Pathology · doi:10.1177/1066896906293055 · Cited by 44
Cited by
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L. B., Larsimont, D., Davies, H., et al. (2015) · Nature Medicine · doi:10.1038/nm.3886 · Cited by 816
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Cellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Aeffner, F., Zarella, M. D., Buchbinder, N., Bui, M. M., Goodman, M. R., Hartman, D. J., Lujan, G. M., Molani, M. A., Parwani, A. V., Lillard, K., et al. (2019) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_82_18 · Cited by 403
Metadata
- Authors
- Seol, H., Lee, H. J., Choi, Y., Lee, H. E., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., & Park, S. Y.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 25
- Issue
- 7
- Pages
- 938-948
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2104159606
- Cited by
- 330
- References
- 33
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.